Enara Bio raises £67.7k to advance Dark Antigen cancer therapies

Developing cancer immunotherapies from genomic dark matter, Enara Bio Limited has raised an estimated £67.7k in its latest funding round. Based in Oxford, the biopharmaceutical company discovers Dark Antigens to create T-cell receptor-based therapies and bispecific T-cell engagers. These treatments are designed for patients with solid tumors, such as lung, breast, and gastrointestinal cancers.

Founded in 2016, Enara Bio addresses the lack of novel, cancer-specific targets by exploring uncharted genomic regions. The company utilizes its EDAPT platform to identify antigens from these regions and its EnTiCE platform to develop bispecific T-cell engagers that target antigens prevalent in solid tumors.

Financial records for the year ended 31 December 2024 show Enara Bio generated £2.6m in revenue while recording a £14.5m loss. The company had 58 employees at the end of 2024, though current LinkedIn data suggests the workforce has grown to 67 people.

The current £67.7k round (allotted in May 2026) follows several larger funding events. In January 2025, the company completed a £10.3m Series B round and two Series A tranches worth £6.1m and £2.5m. During 2024, the firm secured multiple Series B investments, including £13.6m in August and £1m in September. An earlier Series A round in May 2021 raised £11.5m.

Enara Bio is supported by a group of life science investors including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, SV Health Investors, and the Francis Crick Institute. The company also collaborates with Boehringer Ingelheim, which licenses Dark Antigens from Enara Bio to develop its own immunotherapy pipeline.